In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.
Read the full coverage here:
Study reveals ‘paradigm shift’ in non-small cell lung cancer during past decade
Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer
Amivantamab-vmjw shows durable activity in subgroup of patients with advanced NSCLC
Patients with small cell lung cancer have ‘real choice’ in radiotherapy regimen
Pembrolizumab regimen extends OS in advanced malignant pleural mesothelioma
References:
Bogart J, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.01359.
Chi SA, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2002.
Press Release
